Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q7179563> ?p ?o }
Showing triples 1 to 47 of
47
with 100 triples per page.
- Q7179563 subject Q5856563.
- Q7179563 subject Q7335370.
- Q7179563 subject Q7404399.
- Q7179563 subject Q8312632.
- Q7179563 subject Q8334725.
- Q7179563 subject Q8965786.
- Q7179563 abstract "Pexacerfont (BMS-562,086) is a drug developed by Bristol-Myers Squibb which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress. Chronic release of CRF and ACTH is believed to be directly or indirectly involved in many of the harmful physiological effects of chronic stress, such as excessive glucocorticoid release, diabetes mellitus, osteoporosis, stomach ulcers, anxiety, depression, and development of high blood pressure and consequent cardiovascular problems.Pexacerfont is a recently developed CRF-1 antagonist which is currently in clinical trials for the treatment of anxiety disorders, and has also been proposed to be useful for the treatment of depression and irritable bowel syndrome.A recent multicenter, randomized, double-blind, placebo-controlled trial found that Pexacerfont (100 mg/day) did not separate from placebo on the primary outcome measure (the mean change from baseline to end point in the Hamilton Anxiety Scale score). These results suggest that blockade of CRF-1 receptor may not be a feasible treatment for anxiety disorders in certain human populations.".
- Q7179563 atcPrefix "none".
- Q7179563 casNumber "459856-18-9".
- Q7179563 fdaUniiCode "LF1VBG4ZUK".
- Q7179563 iupacName "8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethyl-N-[(1R)-1-methylpropyl]pyrazolo[1,5-a]-1,3,5-triazin-4-amine".
- Q7179563 pubchem "9884366".
- Q7179563 thumbnail Pexacerfont.svg?width=300.
- Q7179563 wikiPageWikiLink Q12206.
- Q7179563 wikiPageWikiLink Q14819907.
- Q7179563 wikiPageWikiLink Q154430.
- Q7179563 wikiPageWikiLink Q165328.
- Q7179563 wikiPageWikiLink Q172941.
- Q7179563 wikiPageWikiLink Q18021818.
- Q7179563 wikiPageWikiLink Q185690.
- Q7179563 wikiPageWikiLink Q266423.
- Q7179563 wikiPageWikiLink Q41861.
- Q7179563 wikiPageWikiLink Q422549.
- Q7179563 wikiPageWikiLink Q4340209.
- Q7179563 wikiPageWikiLink Q4770927.
- Q7179563 wikiPageWikiLink Q5013574.
- Q7179563 wikiPageWikiLink Q5173294.
- Q7179563 wikiPageWikiLink Q5644839.
- Q7179563 wikiPageWikiLink Q5856563.
- Q7179563 wikiPageWikiLink Q7335370.
- Q7179563 wikiPageWikiLink Q7404399.
- Q7179563 wikiPageWikiLink Q8312632.
- Q7179563 wikiPageWikiLink Q8334725.
- Q7179563 wikiPageWikiLink Q8965786.
- Q7179563 atcPrefix "none".
- Q7179563 casNumber "459856".
- Q7179563 iupacName "8".
- Q7179563 pubchem "9884366".
- Q7179563 unii "LF1VBG4ZUK".
- Q7179563 type ChemicalSubstance.
- Q7179563 type Drug.
- Q7179563 type ChemicalObject.
- Q7179563 type Thing.
- Q7179563 type Q8386.
- Q7179563 comment "Pexacerfont (BMS-562,086) is a drug developed by Bristol-Myers Squibb which acts as a CRF-1 antagonist. Corticotropin releasing factor (CRF), also known as Corticotropin releasing hormone, is an endogenous peptide hormone which is released in response to various triggers such as chronic stress. This then triggers the release of corticotropin (ACTH), another hormone which is involved in the physiological response to stress.".
- Q7179563 label "Pexacerfont".
- Q7179563 depiction Pexacerfont.svg.